BACKGROUND: G protein-coupled receptor 119 (GPR119) has emerged as a potential target for the treatment of type 2 diabetes (T2D) and tool compounds have been critical in the evaluation of GPR119 functions. METHODS: We synthesised a novel small-molecule GPR119 agonist, PSN-GPR119, to study GPR119 signalling activities in cells overexpressing GPR119. We measured GPR119-stimulated peptide hormone release from intestinal loops and oral glucose tolerance in vivo from lean (C57BL/6J mouse or Sprague-Dawley (SD) rat) and diabetic (ob/ob mouse or ZDF rat) models. To evaluate the direct effects of GPR119 agonism on gastrointestinal (GI) tissue, we measured vectorial ion transport (measured as ISC; short-circuit current) across rodent GI mucosae and from normal human colon specimens. RESULTS: GPR119 activation by PSN-GPR119 increased cAMP accumulation in hGPR119-overexpressing HEK293 cells (EC50, 5.5 nM), stimulated glucagon-like peptide 1 (GLP-1) release from GLUTag cells (EC50, 75 nM) and insulin release from HIT-15 cells (EC50, 90 nM). In vivo, PSN-GPR119 improved glucose tolerance by ~50% in lean mice or rats and ~60% in the diabetic ob/ob mouse or ZDF rat models. Luminal addition of PSN-GPR119 to isolated loops of lean rat small intestine stimulated GLP-1, glucose insulinotropic peptide (GIP) and peptide YY (PYY) release under basal (5 mM) and high glucose (25 mM) conditions. Activation of GPR119 also reduced intestinal ion transport. Apical or basolateral PSN-GPR119 addition (1 μM) to lean or T2D rodent colon mucosae reduced ISC levels via PYY-mediated Y1 receptor agonism. The GPR119 response was glucose sensitive and was abolished by Y1 receptor antagonism. Similarly, in human colon, mucosa PSN-GPR119 acted via a Y1-specific mechanism. CONCLUSIONS: Our results show that functional GPR119 responses are similar in lean and diabetic rodent, and human colon; that GPR119 stimulation can result in glucose lowering through release of intestinal peptide hormones and that PSN-GPR119 is a useful tool compound for future studies.
BACKGROUND:G protein-coupled receptor 119 (GPR119) has emerged as a potential target for the treatment of type 2 diabetes (T2D) and tool compounds have been critical in the evaluation of GPR119 functions. METHODS: We synthesised a novel small-molecule GPR119 agonist, PSN-GPR119, to study GPR119 signalling activities in cells overexpressing GPR119. We measured GPR119-stimulated peptide hormone release from intestinal loops and oral glucose tolerance in vivo from lean (C57BL/6J mouse or Sprague-Dawley (SD) rat) and diabetic (ob/ob mouse or ZDFrat) models. To evaluate the direct effects of GPR119 agonism on gastrointestinal (GI) tissue, we measured vectorial ion transport (measured as ISC; short-circuit current) across rodent GI mucosae and from normal human colon specimens. RESULTS:GPR119 activation by PSN-GPR119 increased cAMP accumulation in hGPR119-overexpressing HEK293 cells (EC50, 5.5 nM), stimulated glucagon-like peptide 1 (GLP-1) release from GLUTag cells (EC50, 75 nM) and insulin release from HIT-15 cells (EC50, 90 nM). In vivo, PSN-GPR119 improved glucose tolerance by ~50% in lean mice or rats and ~60% in the diabetic ob/ob mouse or ZDFrat models. Luminal addition of PSN-GPR119 to isolated loops of lean rat small intestine stimulated GLP-1, glucose insulinotropic peptide (GIP) and peptide YY (PYY) release under basal (5 mM) and high glucose (25 mM) conditions. Activation of GPR119 also reduced intestinal ion transport. Apical or basolateral PSN-GPR119 addition (1 μM) to lean or T2D rodent colon mucosae reduced ISC levels via PYY-mediated Y1 receptor agonism. The GPR119 response was glucose sensitive and was abolished by Y1 receptor antagonism. Similarly, in human colon, mucosa PSN-GPR119 acted via a Y1-specific mechanism. CONCLUSIONS: Our results show that functional GPR119 responses are similar in lean and diabetic rodent, and human colon; that GPR119 stimulation can result in glucose lowering through release of intestinal peptide hormones and that PSN-GPR119 is a useful tool compound for future studies.
Authors: Katrine B Hansen; Mette M Rosenkilde; Filip K Knop; Niels Wellner; Thi A Diep; Jens F Rehfeld; Ulrik B Andersen; Jens J Holst; Harald S Hansen Journal: J Clin Endocrinol Metab Date: 2011-07-21 Impact factor: 5.958
Authors: Yumi Imai; Hiral R Patel; Evan J Hawkins; Nicolai M Doliba; Franz M Matschinsky; Rexford S Ahima Journal: Endocrinology Date: 2007-08-23 Impact factor: 4.736
Authors: Helen M Cox; Iain R Tough; Anne-Marie Woolston; Lei Zhang; Amy D Nguyen; Amanda Sainsbury; Herbert Herzog Journal: Cell Metab Date: 2010-06-09 Impact factor: 27.287
Authors: Hong Lan; Galya Vassileva; Aaron Corona; Li Liu; Hana Baker; Andrei Golovko; Susan J Abbondanzo; Weiwen Hu; Shijun Yang; Yun Ning; Robert A Del Vecchio; Frederique Poulet; Maureen Laverty; Eric L Gustafson; Joseph A Hedrick; Timothy J Kowalski Journal: J Endocrinol Date: 2009-03-12 Impact factor: 4.286
Authors: Rachel L Batterham; Mark A Cohen; Sandra M Ellis; Carel W Le Roux; Dominic J Withers; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Jeppe H Ekberg; Maria Hauge; Line V Kristensen; Andreas N Madsen; Maja S Engelstoft; Anna-Sofie Husted; Rasmus Sichlau; Kristoffer L Egerod; Pascal Timshel; Timothy J Kowalski; Fiona M Gribble; Frank Reiman; Harald S Hansen; Andrew D Howard; Birgitte Holst; Thue W Schwartz Journal: Endocrinology Date: 2016-10-25 Impact factor: 4.736
Authors: Iain R Tough; Sarah Forbes; Herbert Herzog; Robert M Jones; Thue W Schwartz; Helen M Cox Journal: Endocrinology Date: 2018-04-01 Impact factor: 4.736
Authors: Cheryl A Brighton; Juraj Rievaj; Rune E Kuhre; Leslie L Glass; Kristina Schoonjans; Jens J Holst; Fiona M Gribble; Frank Reimann Journal: Endocrinology Date: 2015-08-17 Impact factor: 4.736